Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma

Oncology Letters

Volumn 7, Issue 2, 2014, Pages 439-443

  He, Guoping ^a   Zhao, Baojian ^b   Zhang, Xu ^b   Gong, Rixiang ^c  

^a ANHUI PROVINCIAL HOSPITAL   (China)

^b AIR FORCE GENERAL HOSPITAL   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

BRAF V600E; Papillary thyroid carcinoma; Prognostic value

Indexed keywords

B RAF KINASE; THYROGLOBULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAF V600E GENE; CANCER PROGNOSIS; CHILD; DISEASE ASSOCIATION; FEMALE; GENE; GENE MUTATION; GENE SEQUENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREVALENCE; RISK FACTOR; SCHOOL CHILD; THYROID PAPILLARY CARCINOMA; VERY ELDERLY;

EID: 84890414356     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1713     Document Type: Article

References (20)

1. Ries LAG, Melbert D, Krapcho M, etal (eds): SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, 2007.
2. Schlumberger M and Pacini F: Prognostic factors. In: Thyroid Tumors. Nucleon Editions, Paris, pp111-125, 2003.
3. Witt RL: Initial surgical management of thyroid cancer. Surg Oncol Clin N Am17: 71-91, 2008.
4. Kim TH, Park YJ, Lim JA, etal: The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer118: 1764-1773, 2012.
5. Xing M, Clark D, Guan H, etal: BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol27: 2977-2982, 2009.
6. Gong RX, Zhou Y, Luo SH, etal: An investigation of BRAF mutation in papillary thyroid carcinoma and its clinical value. Zhonghua Yi Xue Yi Chuan Xue Za Zhi26: 310-313, 2009 (InChinese).
7. Kebebew E, Weng J, Bauer J, etal: The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg246: 466-471, 2007.
8. Davies H, Bignell GR, Cox C, etal: Mutations of the BRAF gene in human cancer. Nature417: 949-954, 2002.
9. DeLuca AM, Srinivas A and Alani RM: BRAF kinase in melanoma development and progression. Expert Rev Mol Med10: e6, 2008.
10. Xing M: BRAF mutation in thyroid cancer. Endocr Relat Cancer12: 245-262, 2005.
11. Ball DW: Selectively targeting mutant BRAF in thyroid cancer. JClin Endocrinol Metab95: 60-61, 2010.
12. Costa AM, Herrero A, Fresno MF, etal: BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol (Oxf) 68: 618-634, 2008.
13. Howell GM, Carty SE, Armstrong MJ, etal: Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer. Ann Surg Oncol18: 3566-3571, 2011.
14. Bollag G, Tsai J, Zhang J, etal: Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov11: 873-886, 2012.
15. Tufano RP, Teixeira GV, Bishop J, etal: BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore) 91: 274-286, 2012.
16. Henderson YC, Shellenberger TD, Williams MD, etal: High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res15: 485-491, 2009.
17. Alzahrani AS and Xing M: Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND. Endocr Relat Cancer29, 13-22, 2013.
18. Bozec A, Dassonville O, Chamorey E, etal: Clinical impact of cervical lymph node involvement and central neck dissection in patients with papillary thyroid carcinoma: a retrospective analysis of 368 cases. Eur Arch Otorhinolaryngol268: 1205-1212, 2011.
19. Elisei R, Viola D, Torregrossa L, etal: The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. JClin Endocrinol Metab97: 4390-4398, 2012.
20. O'Neill CJ, Bullock M, Chou A, etal: BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery148: 1139-1145, 2010.